bpc-157 human clinical trials safety adverse events What is BPC-157? The Hidden Risks of BPC‑157:

Reduce dose seeing if symptoms resolve while maintaining some benefit

T.GhoshS

Neither has been compared head-to-head in a controlled tendon trial

TB-500 is best viewed as a broad-acting peptide that supports systemic healing, angiogenesis, and muscle recovery, while BPC-157 is more localized in action, excelling in tendon, ligament, and gastrointestinal repair

Retatrutide: Maintained at established dose (typically 8 to 12 mg weekly) BPC-157: 0.25 mg daily TB-500: 2.5 mg twice weekly (loading) or 2 mg weekly (maintenance) GHK-Cu: 0.1 to 0.2 mg three times weekly Duration: 8 to 12 weeks maximum, with 30-day minimum break between cycles The injection schedule for the complete GLOW protocol requires careful organization